Search
forLearn
1 / 1 resultsResearch
5 / 1000+ results
research Positive Lymphocyte Transformation Test in a Patient with Allergic Contact Dermatitis of the Scalp After Short-Term Use of Topical Minoxidil Solution
Patient had scalp allergy from minoxidil; test helped identify cause and suggest alternative treatments.
research Contact Dermatitis to Minoxidil
Minoxidil can cause skin irritation like eczema and rash in some users.
research Allergic Contact Dermatitis from Minoxidil
Minoxidil can cause allergic reactions, but testing helps identify the cause.
research Allergic Contact Dermatitis to Minoxidil
Minoxidil can cause allergic reactions like burning, itching, and red bumps.
research Contact Dermatitis in Reaction to 2% Topical Minoxidil Solution
Minoxidil solution can cause skin irritation and allergies in some users.
Community Join
5 / 361 resultscommunity Effects of 2% vs 5% min for sebderm
Switching from 2% liquid minoxidil to 5% foam minoxidil reduced scalp irritation but increased eyebrow flakiness and thinning. The user speculates that propylene glycol in the liquid formulation might have been protecting against seborrheic dermatitis while causing contact dermatitis.
community Topical Fin Vs Oral Fin. Which is better and has less sides?
Comparing the effectiveness and side effects of topical finasteride versus oral finasteride, with people sharing their experiences using both treatments to manage hair loss.
community Is anyone else allergic to Minoxidil
A user experienced a painful rash from both liquid and foam minoxidil, suggesting an allergy to minoxidil itself. They are seeking others with similar experiences.
community Massive Shedding and Itchy Scalp (Fin 1mg 4x/week, Dut 0.5mg 3x/week, Minoxidil 1ml 2x/day)—Seeking Advice
The user experienced significant hair shedding and an itchy scalp after using a combination of Finasteride, Dutasteride, and Minoxidil. They are seeking advice on whether Dutasteride might be causing these issues and are considering adjusting their treatment regimen.
community Kintor Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China
Kintor Pharma completed patient enrollment for a Phase II trial in China for GT20029, a potential new treatment for hair loss. Some believe GT20029 could replace finasteride if effective, while others discuss finasteride's limited efficacy and potential underreported side effects.